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Abbreviations  
AVID Antiarrhythmics versus Implantable Defibrillators 
AMIOVIRT Amiodarone Versus Implantable Cardioverter-Defibrillator 
CAT The Cardiomyopathy Trial 
CIDS Canadian Implantable Defibrillator Study 
COMPANION Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure  
DANISH Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart 
Failure on Mortality  
DEFINITE Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial 
SCD-HeFT Sudden Cardiac Death in Heart Failure Trial 
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ABSTRACT 
Objective  The recent Danish Study to Assess the Efficacy of ICDs [implantable cardioverter 
defibrillators] in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH) trial 
suggested that ICDs do not reduce overall mortality in patients with non-ischaemic cardiomyopathy 
(NICM), despite reducing sudden cardiac death. We performed an updated meta-analysis to examine 
the impact of ICD therapy on mortality in NICM patients. 
 
Methods  A systematic search for studies that examined the effect of ICDs on outcomes in NICM 
was performed. Our analysis compared patients randomised to an ICD with those randomised to no 
ICD, and examined the endpoint of overall mortality. 
 
Results  Six primary prevention trials and two secondary prevention trials were identified that met 
the pre-specified search criteria. Using a fixed-effects model, analysis of primary prevention trials 
revealed a reduction in overall mortality with ICD therapy (RR 0.76, 95% CI 0.65-0.91). 
 
Conclusions Although our updated meta-analysis demonstrates a survival benefit of ICD therapy, 
the effect is substantively weakened by the inclusion of DANISH – which is both the largest and 
most recent of the analysed trials - indicating that the residual pooled benefit of ICDs may reflect the 
risk of sudden death in older trials which included patients treated sub-optimally by contemporary 
standards. As such, these data must be interpreted cautiously.  The results of DANISH emphasise 
that there is no ‘one size fits all’ indication for primary prevention ICDs in NICM patients, and 
clinicians must consider age and comorbidity on an individual basis when determining whether a 
defibrillator is appropriate. 
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KEY QUESTIONS 
 
 
What is already known about this subject? 
 
Evidence for a mortality benefit with implantable cardiac defibrillators in patients with non-
ischaemic cardiomyopathy has always been less robust than for patients with ischaemic 
cardiomyopathy, depending on a meta-analysis of trials which, individually, did not show a 
statistically significant benefit. The results of the recent DANISH trial suggested that ICDs may not 
reduce overall mortality in the modern era. 
 
 
What does this study add? 
 
Our meta-analysis and critical review provides an update in this field. Although a mortality benefit 
of defibrillators in NICM patients is still apparent in our pooled analysis, careful interpretation of 
these data suggest that the neutral result of DANISH may more accurately reflect the utility – or 
relative lack therein – of ICDs in the modern era. In part, this is because contemporary heart failure 
therapy reduces both sudden cardiac death and death from worsening heart failure, thus making an 
additional beneficial effect of defibrillator therapy on overall mortality harder to demonstrate. Closer 
analysis of DANISH suggests that younger patients with little co-morbidity may still benefit from an 
ICD, at least in the medium-term when their functional limitation is not severe.  
 
 
How might this impact on clinical practice? 
 
An individualised approach focusing on risk stratification according to patient age and comorbidity 
is required. 
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INTRODUCTION 
The success of primary and secondary prevention implantable cardioverter defibrillators (ICDs) in 
reducing mortality in patients with coronary artery disease and left ventricular systolic dysfunction 
(LVSD) or heart failure with reduced ejection fraction (HFrEF) is well documented.[1,2,3] 
Concurrent trials seeking to validate the use of ICDs in patients with non-ischaemic cardiomyopathy 
(NICM) have been less successful. Pre-specified subgroup analyses of early secondary prevention 
ICD trials had suggested there was no significant difference in the benefit derived by patients with 
ischaemic cardiomyopathy (ICM) and NICM.[4,5] However, the first two primary prevention ICD 
trials to focus exclusively on NICM recruited only 207 patients between them before stopping early 
for futility.[6,7] Current guidelines for primary prevention ICDs in NICM are based largely on a 
meta-analysis of randomised controlled trials (RCTs).[8,9,10] In a combined analysis of five primary 
prevention trials, Desai et al reported a significant reduction in all-cause death in patients randomised 
to an ICD compared with medical therapy: RR 0.69; 95% CI, 0.55-0.87; p=0.002.[10] However, the 
validity of these findings in the contemporary era has been cast into doubt by the results of the recent 
Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure 
on Mortality (DANISH) trial, which found that ICDs did not reduce overall mortality.[11] We 
conducted an updated meta-analysis to examine the efficacy of primary prevention ICDs in NICM. 
 
METHODS 
Search strategy and study selection 
We sought to determine the treatment effect of ICDs on all-cause death in NICM patients enrolled 
into primary (and, as a sub-analysis, secondary) prevention trials. We systematically identified 
published RCTs using computer-aided searches of Medline and Embase (from 1946 or 1947 
respectively) to January 2017, using the terms “defibrillator” and “implantable” as search terms in 
the abstract, MeSH subject heading, keyword heading or title fields. Restrictions and eligibility 
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criteria are detailed in the supplementary appendix. Eligible studies were subcategorised into primary 
and secondary prevention trials, with only primary prevention trials selected for the primary meta-
analysis, due to the assumption of highly heterogeneous baseline risk between these populations; 
secondary prevention trials were included in a secondary pooled analysis. A Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart detailing the selection 
process is presented in Figure 1. 
FIGURE 1 HERE 
 
Statistical analysis 
We used summary statistics from the individual trials because patient-level data were not available 
for all studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) regarding all-cause mortality 
in both ICD and control groups from original trial results papers were used as the principal summary 
measures where available. Single-study estimates were combined using inverse variance-weighted 
averages of logarithmic RRs in both fixed- and random-effects analysis. Heterogeneity between 
studies was assessed using the I2 statistic. In the absence of significant heterogeneity the fixed-effect 
estimate was used. Pre-specified sensitivity analyses assessed the contribution of any single trial to 
the pooled estimate by recalculating the pooled RR after excluding single trials one by one. To 
determine the effect of follow-up duration in primary prevention trials, pooled estimates were 
recalculated separately for trials with a mean or median follow-up of less than three years, and three 
or more years. Publication bias was sought using a funnel plot [supplementary appendix Figure 1] 
and Eggers’s test for small-study effects.  
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RESULTS 
Eight randomised controlled trials were identified that met the pre-specified search criteria, of which 
six were primary prevention trials, and two were secondary prevention trials. The design and 
population characteristics of these trials are summarised in Table 1. We present a narrative overview 
of the primary prevention trials, followed by the results of our meta-analysis. 
 
Overview of primary prevention ICD trials included in this meta-analysis 
Pre-DANISH 
As already discussed, the first two primary prevention ICD trials to focus exclusively on NICM were 
halted early due to futility.[6,7] In the Cardiomyopathy Trial (CAT) this was due at least in part to 
the unexpectedly low event rate, with interim analysis revealing a 1-year mortality rate of only 5.6% 
for all patients.[6] 
 
The Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial 
subsequently randomised 458 patients with NICM treated with standard medical therapy to an ICD 
for primary prevention purposes or no ICD.[12] Patients were predominantly in New York Heart 
Association (NYHA) functional class III and rates of angiotensin-converting enzyme (ACE) inhibitor 
and beta-blocker use were 86% and 85%, respectively (Table 1). Mineralocorticoid receptor 
antagonists (MRAs) were not recommended as standard therapy at that time, and rates of their use 
were not reported. Over a mean follow-up of 29 months there were only 68 deaths. Although there 
was a significant reduction in arrhythmic sudden death in the ICD group (HR 0.20, 95% CI 0.06 to 
0.71; p=0.006), there was no difference in all-cause death (HR 0.65; 95% CI 0.40 to 1.06; 
P=0.08).[12] The rate of arrhythmic death was lower than anticipated, comprising only a third of all 
deaths in the standard-therapy arm.[12] 
 
 9 
The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) randomised 2521 patients with HFrEF 
to placebo, amiodarone or an ICD.[13] The majority of patients were in NYHA functional class II 
and almost half had NICM. The rate of prescription of an ACE inhibitor was similar to that in 
DEFINITE (83-87%), but beta-blocker use was lower (69%), and only 20% of patients were 
prescribed a MRA at baseline. Overall, ICD treatment reduced all-cause death by 23% (HR 0.77; 
97.5% CI 0.62 to 0.96; P=0.007). The benefit of ICD therapy appeared to be greatest in patients in 
NYHA functional class II, consistent with other studies which have shown that patients with more 
advanced symptoms are more likely to die from pump failure.[14,15,16] Although patients with a 
non-ischaemic aetiology were at lower risk than those with an ischaemic aetiology, the reduction in 
all-cause death was similar in each subgroup: non-ischaemic HR 0.73 (95% CI 0.50-1.07) and 
ischaemic HR 0.79 (95% CI 0.60–1.04).  
  
The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure trial 
(COMPANION) randomised 1520 heart failure patients in NYHA functional class III and IV to 
standard medical therapy alone or in conjunction with either a cardiac resynchronisation pacemaker 
(CRT-P) or cardiac resynchronisation defibrillator (CRT-D).[17] Both ICM and NICM patients were 
included. Among patients with non-ischaemic cardiomyopathy, CRT-D therapy led to a lower risk 
of all-cause death, as compared with pharmacological therapy (HR 0.50; 95% CI 0.29-0.88). In 
patients with ischemic cardiomyopathy, the HR was 0.73 (95% CI 0.52-1.04).   
 
When considering the meta-analysis by Desai et al, it is important to note that, for the COMPANION 
trial, the treatment effect analysed was that between groups receiving CRT-D and pharmacotherapy, 
ignoring the CRT-P group.[10] Thus, in this analysis, assessment of the effect of ICD therapy was 
confounded by the coupled effect of CRT. However, the efficacy of ICD therapy remained 
statistically significant even if COMPANION was excluded, ie. even after removing all CRT-D 
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patients. Recently, a comparison of the effect of CRT-D with CRT-P (on top of medical therapy) 
from COMPANION trial was published [18]: the hazard ratio for all-cause death was 0.84 (0.65, 
1.09); for cardiovascular death it was 0.73 (0.55, 0.98) and for sudden death 0.37 (0.21, 0.65). It is 
instructive to compare these findings with the DANISH trial, where the background use of CRT-P 
was frequent. 
 
The DANISH trial 
The DANISH trial enrolled 1116 patients with heart failure due to NICM, randomising them to 
conventional therapy (medical treatment and CRT-P if indicated) or an ICD added to conventional 
therapy.[11] Patients were almost exclusively in NYHA functional class II-III. After a median follow-
up of 5.6 years, there was no reduction in the primary endpoint of all-cause death (251 deaths in total) 
for patients randomised to ICD therapy (HR 0.87; 95% CI 0.68-1.12; p=0.28). This was despite a 
significant reduction in sudden cardiac death in the ICD group (HR 0.50; 95% CI 0.31-0.82; 
p=0.005), although there was a total of only 70 patients with sudden cardiac death in the trial. The 
hazard ratio for cardiovascular death (172 deaths) was 0.77 (95% CI 0.57-1.05; p=0.10). 
Rates of evidence-based medical therapy for heart failure were high in DANISH and more than half 
of patients (58%) received CRT, unlike those in previous ICD trials, with the exception of 
COMPANION. However, there was no evidence that background CRT explained the lack of benefit 
of ICD implantation. Specifically, in DANISH, the HR for the ICD group compared with the control 
group was 0.83 (95% CI 0.58−1.19) for individuals without CRT and 0.91 (95% CI 0.64−1.29) in 
those with CRT, with an interaction P-value of 0.73. 
More relevant is the fact that both optimal medical therapy and CRT reduce the risk of each of sudden 
cardiac death and pump failure death and, therefore, cardiovascular death overall.[8,9] As a result, 
patients with an already relatively low absolute risk of sudden death because of their non-ischaemic 
(compared with ischaemic) aetiology, receiving excellent medical and device treatment, had little 
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room for further reduction in this mode of death (and for any reduction in sudden cardiac death to 
reduce cardiovascular death and, consequently, all-cause death). Illustrating this, the absolute rate of 
sudden cardiac death was low even in the control group (8.2% of patients in the control group suffered 
sudden cardiac death – less than 2% per year), as was sudden cardiac death as a proportion of 
cardiovascular death (48% in the control group). Furthermore, cardiovascular mortality comprised 
only 73% of all-cause death in the control group, which is relatively low compared to older heart 
failure trials [19]. This exemplifies the falling burden of sudden cardiac death and cardiovascular 
mortality in heart failure trials, attributable to modern treatment strategies, which are effective at 
reducing these causes of death [19].  
Consequently, in a contemporary trial involving optimally-treated patients, such as was DANISH, 
even a large relative risk-reduction in sudden cardiac death will have a small impact on overall 
mortality if only a modest proportion of all deaths are cardiovascular and, in turn, only a moderate 
proportion of those are sudden. In addition, in patients with heart failure, there is the competing risk 
of non-sudden cardiovascular death, particularly death from worsening pump failure i.e. by 
preventing only one of the two common modes of death in heart failure, ICDs may effectively switch 
the mode of cardiovascular death, especially as severity of heart failure increases over time (this is 
how ICDs, notably, differ from drugs which reduce each of the two main modes of death in heart 
failure). Of course, when all-cause death is the primary endpoint, there is also the competing risk of 
non-cardiovascular death which is more common in older individuals with more co-morbidity and 
which increases proportionately during longer-term follow-up as non-cardiovascular co-morbidity 
develops with age. In this context, two findings of DANISH are notable. Firstly, there was a 
significant interaction between the effect of ICD treatment and age, whereby ICD treatment seemed 
to be of more benefit in younger compared with older patients: in patients <59 years HR 0.51 
(0.29−0.92), in those aged ≥59 to <68 years HR 0.75 (0.48−1.16) and in those ≥68 years HR 1.19 
(0.81−1.73). Secondly, there was a suggestion that the proportional-hazard assumption for all-cause 
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death was violated (i.e. when tested with Schoenfeld residuals, the P value was 0.054) and in keeping 
with this the Kaplan-Meier curves appeared to diverge during the initial 5 years of treatment where-
after they converged. Overall, these findings can be interpreted as suggesting that ICDs reduce all-
cause death in younger patients with little co-morbidity, at least in the short-term before the severity 
of heart failure increases with time (leading to a relatively higher risk of pump failure death) and co-
morbidity develops (leading to a greater likelihood of non-cardiovascular death).  
 
Results of meta-analysis  
We did not include secondary prevention trials in our main meta-analysis. Pooled analysis of the six 
primary prevention trials (Figure 2), representing 2970 patients with NICM, demonstrated a 24% 
reduction in all-cause death with an ICD.  
FIGURE 2 HERE 
 
In a sensitivity analysis the benefit of ICD therapy was maintained after the removal of any single 
study from the pooled analysis. Neither did the exclusion of any single study, except DANISH, very 
substantively alter the magnitude of benefit from ICD therapy. If DANISH was excluded, the effect 
of ICD therapy was greater (RR 0.68; 95% CI 0.54–0.86, p=0.001). We performed a sensitivity 
analysis designed to test the effect of length of follow-up (average follow-up of each trial is listed in 
Table 1). Pooled analysis of primary prevention trials with less than 3 years follow-up showed a trend 
to greater benefit for ICD therapy (RR 0.61; 95% CI 0.43–0.86) compared to pooled analysis of trials 
with longer follow-up (RR 0.82; 95% CI 0.68–1.00) however the difference between these groups 
was not significant (P value for interaction = 0.13). The failure to reach statistical significance may 
be a result of having only three trials in either of these subgroups.  
Pooled analysis of the six primary and two secondary prevention trials in combination (representing 
3226 patients) also demonstrated a 24% reduction in all-cause death with ICD therapy (RR 0.76, 
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p=0.001). Variation in the pooled RR due to trial heterogeneity was not significant (I2=0%; we 
therefore used a fixed-effects model although the estimate was identical in a random-effects model). 
We did not detect significant publication bias (supplementary appendix Figure 1). 
 
We also examined the effects of defibrillator therapy on all-cause death when added to CRT (and 
medical therapy) in the two relevant primary prevention trials (COMPANION and DANISH). In 
total, these trials included 917 patients with CRT-D and 940 patients with CRT-P. There was a total 
of 364 deaths among these patients. Pooled analysis of these subgroups from COMPANION and 
DANISH did not demonstrate a benefit of CRT-D over CRT-P (Figure 3). It should be noted that 
ICM as well as NICM patients from COMPANION were included in this analysis, since outcomes 
for patients receiving CRT-D and CRT-P in COMPANION are not available broken down by 
aetiology. However, since ICM patients are no less likely to benefit from ICDs than NICM patients, 
their inclusion is unlikely to underestimate the benefit of defibrillator therapy.  
FIGURE 3 HERE 
 
 
 
 
 
  
 14 
DISCUSSION 
What now for primary prevention ICDs in NICM? DANISH is the largest and most contemporary 
trial to address this issue, and its results are thought-provoking and potentially challenge current 
guidelines. Although our updated meta-analysis of primary prevention trials in NICM continues to 
show a significant survival benefit of ICD therapy, the inclusion of DANISH weakened this effect 
and the residual benefit may reflect the risk of sudden cardiac death in older trials which included 
patients treated sub-optimally by contemporary standards. In keeping with this, our meta-analysis of 
patients randomised to CRT-D versus CRT-P (on top of medical treatment) did not demonstrate a 
statistically significant survival advantage of defibrillator therapy in patients receiving CRT and 
pharmacological treatment. Nevertheless, our analysis does not completely exclude the possibility of 
a modest impact of an ICD on all-cause death, given the relatively small number of events and the 
wide confidence intervals around the point estimate for the treatment effect of defibrillator therapy 
(0.87, 0.72-1.05). However, even if there was a modest reduction in all-cause death with ICD 
treatment, it was obtained in patients who were not optimally medically treated. A beta-blocker was 
used in only 67% of patents in COMPANION, a rate of use which is low by contemporary 
standards.[20] In DANISH, MRA use was less than 60% and sacubitril-valsartan was not available. 
Both these therapies reduce sudden cardiac death and all-cause death.[8,21] The absolute benefit of 
an ICD is likely to diminish with further reductions in the absolute rate of cardiovascular death, and 
when the proportion of deaths due to cardiovascular causes is smaller, as will be the case in patients 
treated with better background medical and device therapy (i.e. CRT). In this scenario, even if they 
are effective, ICDs may not be cost-effective.  
 
So which patients with NICM might obtain a worthwhile benefit from a primary prevention ICD? 
Subgroup analysis of DANISH suggested a reduction in all-cause death with ICD therapy in younger 
patients, as detailed above. The age subgroup analysis of DANISH suggested that the number of 
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premature deaths avoided per 100 patients treated for a median of 5 years was approximately 7.6 in 
those aged <59 years and 3.5 in individuals aged 59-to-67 years, giving numbers needed to treat 
(NNT) of 13 and 29, respectively. While at face value the absolute benefit in younger individuals 
looks clinically meaningful, accepting the potential for better background medical therapy, there is 
one other important consideration. ICDs are not without adverse effects. The delivery of 
inappropriate therapies has been reported in almost one-fifth of ICD recipients.[22] These constitute 
up to half of all shocks, despite advances in device programming [23] and are associated with an 
increase in mortality [23,24]. Other complications of ICD (or indeed CRT) implantation include lead 
fracture, device failure, and infection necessitating system extraction. The potential benefits of ICDs 
must always be weighed against these risks. Recent data from the USA show that older patients are 
at greater risk of complications after receiving an ICD.[25] These are also the patients less likely to 
benefit from an ICD. In DANISH, the rate of death from any cause among patients receiving an ICD 
in the age group <59, 59-to-67 and ≥68 was 10%, 21% and 31%, respectively. This implies that older 
patients die more frequently from causes that are not prevented by ICD therapy, such as pump failure 
and non-cardiovascular conditions. Since patients with heart failure in the real world are older and 
are afflicted by more comorbidities than those in clinical trials, these competing risks are likely to be 
more prevalent.  
 
These new findings may help address the biggest challenge we have in using ICDs - identifying the 
minority of patients who have the optimum benefit/risk balance for a primary prevention ICD.  
Clearly, the patients with NICM included in the existing trials are heterogeneous both in terms of 
aetiology and with respect to risk of sudden death. However, to date, the trials have provided little 
information about either type of subgroup. A vast array aetiological, functional, electrocardiographic, 
biomarker, and imaging variables have been evaluated in the quest to identify the patients who might 
have most to gain from an ICD. Although it is beyond the scope of this paper to analyse this 
 16 
information, it is safe to say that no variable has yet proven sufficiently sensitive and specific for 
predicting SCD (as opposed to other modes of death). Currently, the most promising approach seems 
to be cardiac magnetic resonance imaging with late gadolinium enhancement to identify myocardial 
scar or fibrosis which is a substrate for ventricular re-entrant arrhythmias, although further 
prospective evaluation in NICM is required. The results of DANISH suggest that age and co-
morbidity may be more valuable than these other investigations. The findings of DANISH also 
highlight the need to continually reassess the value of an ICD in each individual patient over time, 
with increasing age and the potential development of co-morbidity and worsening of heart failure 
symptoms (and the emergence of competing risks of non-cardiovascular death and death from 
worsening heart failure, respectively). The European Society of Cardiology 2016 heart failure 
guidelines, consistent with other guidelines, recommend an ICD in patients with NICM “to reduce 
the risk of sudden death and all-cause mortality in patients with symptomatic heart failure (NYHA 
class II–III), and a left ventricular ejection fraction ≤35% despite ≥3 months of optimal medical 
therapy, provided they are expected to survive substantially longer than one year with good functional 
status (class I, level B).” It may be premature to suggest any change in the wording of the guidelines, 
especially as it is likely that further analyses of DANISH will be conducted and published which may 
help answer this question. However, the wording of the guidelines may not need any substantial 
change because the decision to implant an ICD will still be determined by functional status and life-
expectancy, both of which are determined, in part, by age and co-morbidity. Indeed, the supporting 
text of current guidelines also states that “Patients with serious co-morbidities who are unlikely to 
survive substantially more than 1 year are unlikely to obtain substantial benefit from an ICD”, which 
is consistent with the findings of DANISH. A suggested clinical approach to a patient being 
considered for an ICD is presented in Figure 4. The current guidelines also recognise that the 
appropriateness of an ICD may change over time and that the value of an ICD in an individual patient 
should always be re-assessed when generator replacement is needed. Deactivation of an ICD may 
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even be considered in certain circumstances e.g. in a patient receiving terminal care for heart failure 
or a non-cardiovascular illness. We believe that the findings of DANISH also support these 
recommendations.  
INSERT FIGURE 4 HERE 
 
Although DANISH was conducted in only one European country and the benefits and risks identified 
may not apply exactly to patients in other countries, the principles illustrated do relate more generally 
and should be individually applied to patients with NICM. 
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Table 1:  Baseline patient characteristics in primary and secondary prevention ICD trials enrolling NICM patients  
  Secondary prevention trials  Primary prevention trials 
Characteristic AVID CIDS   CAT AMIOVIRT DEFINITE COMPANION SCD-HeFT DANISH 
Year of publication 1997 2000   2002 2003 2004 2004 2005 2016 
No. randomised 1016 659   104 103 458 
(CRT-D vs CMT) 
903 
(ICD vs placebo) 
1676 
1116 
No. (%) with NICM 193 (19.0) 63 (9.6)   104 (100) 103 (100) 458 (100) 397 (44.0) 792 (47.3) 1116 (100) 
Follow-up, mean (SD), mo 18.2 (12.2) 35   66 (26.4) 24 (14.4) 29 (14) Range 14.8 - 16.0 45.5 67.6 (NR) 
Demographics          
 Age, mean (SD), y 65 (10.5) 64 (9.6)   52 (11) 59 (11.5) 58 67 60 64* 
 Male, % (No.) 80 (808) 84.5 (557)   80 (83) 70 (72) 71 (326) 68 (611) 77 (1294) 72 (809) 
 NYHA class III/IV, % (No.) 9.5  (97) 10.8 (71)   34.6 (36) 20 (20) 21 (96) 100 (903) 31 (516) 47 (519) 
 Duration of CHF, mean NR NR   3 mo 3.2 y 2.8 y 3.5 y 24.5 mo 19 (NR)* 
  LVEF, mean (SD), % 31 (13) 34 (14)   24 (7) 23 (9) 21 (14) 22 25 25 (NR)* 
Medications at baseline, % (No.)         
 Ace inhibitor / ARB 68.5 (680) NR   96.2 (100) 85 (88) 96.7 (443) 90 (810) 96 (1610) 97 (1077) 
 Beta-blocker 29.4 (292) 27.4 (181)   3.8 (4) 51.5 (53) 84.9 (389) 67 (608) 69 (1157) 92 (1026) 
 MRA NR NR   NR 19.4 (20) NR 55 (496) 20 (333) 58 (646) 
  
CRT 0 0   0 0 
4.8 (11) in ICD 
group; NR in 
controls 
66 (595) in 
treatment group 
NR 58 (645) 
Design   
ICD vs 
antiarrhythmic 
ICD vs amio.   ICD vs CMT ICD vs amio. ICD vs CMT 
CRT-D vs CRT-P vs 
CMT 
ICD vs amio. vs 
placebo 
ICD vs CMT 
 Primary endpoint ACM ACM   ACM ACM ACM ACM / ACH ACM ACM 
  
Control 1-yr mortality, % 
(No./total) 
18 (90/509) 11 (37/331)   4 (2/54) 10 (5/52) 6 (14/229) 19 (59/308) NR 4 (20/560) 
ICD (Transvenous/Epicardial), % 93 / 5 84 / 10   100 / 0 100 / 0 100 / 0 100 / 0 100 / 0 100 / 0 
Internal validity          
 Follow-up, % 100 100   100 100 100 >95% 100 100 
 Crossovers to ICD, % (No.) 18.9 (96)† 15.7 (52)   NR 15.4 (8) 10 (23) 26 (80)†† NR 4.8 (27) 
 Crossovers to control % (No.) 25.7 (130) 28.1 (92)   NR 21.6 (11) 1.7 (4) NR NR 7.9 (44) 
 Intention-to-treat Yes Yes   NR Yes Yes Yes Yes Yes 
  Events committee NR Not blinded   NR Blinded Blinded Blinded Blinded Blinded 
Abbreviations: ACE, angiotensin-converting enzyme; ACH, all-cause hospitalisation; ACM, all-cause mortality; Amio., amiodarone; ARB, angiotensin-receptor blocker; CHF, congestive heart failure; CMT, conventional medical therapy; CRT-D, 
cardiac resynchronisation therapy defibrillator; CRT-P, cardiac resynchronisation therapy pacemaker; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NICM, 
non-ischaemic cardiomyopathy; NR, not reported; NYHA, New York Heart Association. 
* Calculated as mean of stated medians for treatment and control groups     
† For AVID, crossover rates are reported at 2 years        
†† For COMPANION, rate of withdrawal from medical therapy group is reported as crossover rate    
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
flow diagram. ICD, implantable cardioverter defibrillator; MI, myocardial infarction; NICM, 
non-ischaemic cardiomyopathy; RCT, randomised controlled trial.  
 
Figure 2 All cause mortality among patients with non-ischaemic cardiomyopathy randomised 
to implantable cardioverter defibrillator (ICD) or cardiac resynchronisation therapy 
defibrillator (CRT-D) versus medical therapy or medical therapy plus cardiac 
resynchronisation pacemaker (CRT-P) in primary prevention trials.  
 
 
Figure 3 All-cause mortality among patients randomised to cardiac resynchronisation therapy 
defibrillator (CRT-D) or cardiac resynchronisation therapy pacemaker (CRT-P) in primary 
prevention trials.  
 
 
Figure 4 Suggested approach to consideration of an implantable cardioverter defibrillator 
(ICD) in a patient with non-ischaemic cardiomyopathy. HF, heart failure; LVEF, left 
ventricular ejection fraction; MDT, multi-disciplinary team; NYHA, New York Heart 
Association; OMT, optimal medical therapy  
 
SUPPLEMENTARY APPENDIX: Methods for study selection, data synthesis and 
statistical analysis 
 
We sought to determine the treatment effect of ICDs on all-cause death in NICM patients 
enrolled into primary (and, as a sub-analysis, secondary) prevention trials. Our overall search 
strategy is presented in the main manuscript. Restrictions were imposed to limit the search to 
randomised controlled trials (RCTs) enrolling human subjects that were reported in English. 
To be eligible for inclusion in our meta-analysis, trial populations had to include patients with 
non-ischaemic cardiomyopathy. Trials that only enrolled patients awaiting heart 
transplantation were excluded. Trials had to include randomisation to an implantable cardiac 
defibrillator (ICD) or to a non-ICD control group. The majority of these ICDs were required to 
be transvenous systems, with epicardial systems deemed a priori to be a qualitatively different 
intervention. Trials in which mortality was a primary or composite outcome of the comparison 
of ICDs versus the control group were included. Trial titles and abstracts were initially 
screened, with potentially eligible trials subsequently undergoing more detailed analysis of the 
primary results paper. The risk of bias of individual studies was assessed using the Cochrane 
Collaboration’s tool for assessing risk of bias in RCTs. All trials were deemed either of low or 
unclear risk, with none deemed high risk; bias across studies was deemed unclear. Our analysis 
was not stratified further according to potential bias. This approach was agreed by all authors; 
no protocol is available. 
 
Where HRs were not stated, risk ratios (RRs) and 95% CIs were generated using available data. 
Data were cross-checked against those used by Desai et al.[16] Data sought are presented in 
Table 1 of the main manuscript, with the exception of HR/RRs and 95%CIs, which are 
presented for individual trials in Figures 2 and 3 of the main manuscript. 
  
APPENDIX FIGURE 1 HERE 
This analysis has two limitations at review level. First, it was conducted using trial-level data 
rather than gold-standard, patient-level data, which were unavailable. Second, data for the 
COMPANION trial compared the treatment effect across CRT-D and pharmacotherapy 
groups, rather than comparing CRT-D and CRT-P groups. The potentially confounding effect 
of this is made clear in the main text of the manuscript. All analyses were conducted using 
STATA version 14.0 (StataCorp, College Station, TX). This work was not funded and there 
was no role of any funding source in the conception, data synthesis, analysis, interpretation, or 
in drafting of the manuscript. 
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